The role and therapeutic targeting of IL-6 in rheumatoid arthritis
Explore this paper's citation graph
Summary
The role of IL-6 in the inflammatory conditions and howIL-6 contributes to pathogenesis of RA, what induces IL- 6 and how IL-8 expression is regulated are reviewed.
- Type
- review
- Published
- 2017-03-03
- Cited by
- 195
- References
- 167
- OpenAlex
- https://openalex.org/W2612729795
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:46791654
Keywords
Tocilizumab, Medicine, Rheumatoid arthritis, Immunology, Monoclonal antibody
References
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA
- Baricitinib for the treatment of rheumatoid arthritis
- Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.
- Two distinct and independent sites on IL‐6 trigger gp 130 dimer formation and signalling.
- Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis
- Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial
- Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery.
- Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBζ
- Interleukin‐6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis
- AT‐Rich–Interactive Domain–Containing Protein 5A Functions as a Negative Regulator of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt–Induced Th17 Cell Differentiation
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
- Interleukin-6 family of cytokines and gp130.
- Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms.
- Brief Report: Leucine‐Rich α2‐Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti–Interleukin‐6 Biologic Therapy in Rheumatoid Arthritis
- Interleukin-6: Biology, signaling and strategies of blockade.
- Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130
- Interleukin-6 and the acute phase response.
- The IL-6-Soluble IL-6Rα Autocrine Loop of Endothelial Activation as an Intermediate Between Acute and Chronic Inflammation: an Experimental Model Involving Thrombin
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
Cited by
- Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
- Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?
- Short-term application of tocilizumab during myocardial infarction (STAT-MI)
- NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer
- TXNDC5 contributes to rheumatoid arthritis by down‐regulating IGFBP1 expression
- The moderating role of job resources in the relationship between job demands and interleukin‐6 in an Italian healthcare organization
- Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish
- Smoking and female sex as key risk factors associated with severe arthralgia in acute and chronic phases of Chikungunya virus infection.
- Anti-Inflammatory Effects of p-Coumaric Acid, a Natural Compound of Oldenlandia diffusa, on Arthritis Model Rats
- Cytokine targeting in rheumatoid arthritis.
- Interleukin-6: designing specific therapeutics for a complex cytokine
- Montelukast inhibits inflammatory response in rheumatoid arthritis fibroblast‐like synoviocytes
- Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?
- Régulation of tolerogenicity and immunogenicity
- Synovial GATA1 mediates rheumatoid arthritis progression via transcriptional activation of NOS2 signaling
- IL-6/IL-10 Ratio as A Prognostic and Predictive Marker of the Severity of Inherited Epidermolysis Bullosa.
- Long Non-Coding RNA GAPLINC Promotes Tumor-Like Biologic Behaviors of Fibroblast-Like Synoviocytes as MicroRNA Sponging in Rheumatoid Arthritis Patients
- LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease
- Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals
- Pathogenesis of adult onset still’s disease: current understanding and new insights
Related papers
- Interluekin-17A (IL17A)
- Psoriasis and the TNF/IL23/IL17 axis.
- Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis
- Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases
- Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
- Monocyte Derived Interleukin (IL)-23 Is an Important Determinant of Synovial IL-17A Expression in Rheumatoid Arthritis
- Neutrophils Are Essential As A Source Of Il-17 In The Effector Phase Of Arthritis
- Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis
- Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis.
- IL-12 and IL-23/Th17 axis in systemic lupus erythematosus